Genprex (GNPX) Other Operating Expenses (2016 - 2026)
Genprex (GNPX) posted quarterly Other Operating Expenses of -$290199.0 for Q1 2026, down 134.88% year-over-year from $832082.0 in Q1 2025, and down 104.55% quarter-over-quarter from $6.4 million in Q4 2025.
Genprex (GNPX) Other Operating Expenses (2016 - 2026) Analysis & Trends
Genprex's Other Operating Expenses history runs 11 years deep, the most recent figure standing at -$290199.0 for Q1 2026.
- In Q1 2026, Other Operating Expenses fell 134.88% year-over-year to -$290199.0; the TTM figure through Mar 2026 stood at $5.9 million (up 157.68% YoY), while the FY2024 annual figure was $6693.0, down 55.39% from the prior year.
- Other Operating Expenses for Q1 2026 stood at -$290199.0, down from $6.4 million in the prior quarter.
- The five-year high for Other Operating Expenses was $6.4 million in Q4 2025, with the low at -$5.4 million in Q1 2024.
- The 5-year median for Other Operating Expenses is $3837.0 (2023), against an average of $165274.3.
- Peak annual rise in Other Operating Expenses reached 184884.76% in 2024, while the deepest fall reached 135773.88% in 2024.
- Genprex's Other Operating Expenses stood at $6078.0 in 2022, then plunged by 43.63% to $3426.0 in 2023, then jumped by 184884.76% to $6.3 million in 2024, then climbed by 0.58% to $6.4 million in 2025, then plunged by 104.55% to -$290199.0 in 2026.
- Business Quant data shows GNPX's Other Operating Expenses at -$290199.0 in Q1 2026, $6.4 million in Q4 2025, and -$293770.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Genprex | 1.88 Mn | -13.28 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -290,199.00 |
| Dec 31, 2025 | 6.37 Mn |
| Sep 30, 2025 | -293,770.00 |
| Jun 30, 2025 | 129,926.00 |
| Mar 31, 2025 | -123,554.00 |
| Dec 31, 2024 | 6.34 Mn |
| Sep 30, 2024 | -1.39 Mn |
| Jun 30, 2024 | -2.53 Mn |
| Mar 31, 2024 | -5.45 Mn |
| Dec 31, 2023 | 3,426.00 |
| Sep 30, 2023 | 3,724.00 |
| Jun 30, 2023 | 3,837.00 |
| Mar 31, 2023 | 4,016.00 |
| Dec 31, 2022 | 6,078.00 |
| Sep 30, 2022 | 6,224.00 |
| Jun 30, 2022 | 6,544.00 |
| Mar 31, 2022 | 6,730.00 |
| Dec 31, 2021 | 6,955.00 |
| Sep 30, 2021 | 6,489.00 |
| Jun 30, 2021 | 2,848.00 |